GlassScriptPhysician profile
Ian M Ward
NPI 1922326446
$7,574.75
in general payments reported to CMS, 2019-2025
32 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,894 · 2024: $3,514 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,309 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,308.82 |
| Education | $265.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,500.02 | 2023-2025 | Tavneos, Krystexxa, Enbrel |
| Abbvie INC. | $1,417.78 | 2023-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $892.27 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $685.52 | 2023-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $527.66 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $489.37 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $215.34 | 2024-2025 | Acthar |
| Glaxosmithkline, LLC. | $189.29 | 2023-2024 | Benlysta, Nucala |
| Organon LLC | $178.22 | 2023-2025 | Renflexis, Hadlima |
| Astrazeneca Pharmaceuticals LP | $168.06 | 2023-2025 | Saphnelo |
| Lilly USA, LLC | $157.05 | 2023-2025 | Taltz, Zepbound |
| Sobi, INC | $142.06 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $136.26 | 2023-2025 | Tyenne, Idacio |
| Sandoz INC. | $132.17 | 2023-2025 | Hyrimoz, Jubbonti |
| Actelion Pharmaceuticals US, INC. | $97.10 | 2024 | Opsumit, Uptravi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $91.22 | 2024 | |
| Radius Health, INC. | $76.61 | 2024-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $62.43 | 2023-2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $62.38 | 2025 | Lupkynis |
| Horizon Therapeutics Plc | $49.84 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.53 | 2024 | |
| Janssen Scientific Affairs, LLC | $44.85 | 2025 | Tremfya |
| Kiniksa Pharmaceuticals, LTD. | $36.08 | 2023 | Arcalyst |
| Tersera Therapeutics LLC | $25.58 | 2024 | Quzyttir |
| Mylan Institutional INC. | $24.80 | 2023 | Hulio |
| Takeda Pharmaceuticals U.S.A., INC. | $22.71 | 2025 | Cuvitru |
| Boston Scientific Corporation | $20.65 | 2025 | Wavewriter Alpha Prime 16 |
| Celgene Corporation | $20.45 | 2024 | Orencia |
| Kiniksa Pharmaceuticals International, Plc | $20.17 | 2024 | Arcalyst |
| Almatica Pharma LLC | $15.23 | 2025 | Teriparatide |
| Genentech USA, INC. | $14.18 | 2025 | Gazyva |
| Octapharma USA, INC. | $13.87 | 2024 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.